ERBB2 and breast carcinoma: Although a recent report shows that as a single agent, neoadjuvant treatment with paclitaxel induces tumor response in 92% of patients with erbB2-overexpressing breast cancer [39], our findings suggest that the presence of MM-121 may convert the tumors from non-responsive to responsive to the lower doses of paclitaxel with less side effects, and therefore merit translational implications in the clinic.